Regeneron Pharmaceuticals (REGN) Gross Profit (2009 - 2026)

Regeneron Pharmaceuticals has reported Gross Profit for 18 years, with the latest figure at $3.9 billion in Q2 2026.

• On a quarterly basis, Gross Profit rose 15.59% year-over-year to $3.9 billion in Q2 2026; TTM through Jun 2026 was $14.2 billion, a 8.54% increase from a year earlier, with the FY2025 full-year figure at $13.2 billion, up 0.67% from the prior year.
• Gross Profit was $3.9 billion for Q2 2026 at Regeneron Pharmaceuticals, up from $3.2 billion in the prior quarter.
• The five-year high for Gross Profit was $3.9 billion in Q2 2026, with the low at -$178.0 million in Q4 2022.
• Average Gross Profit over 5 years is $3.0 billion, with a median of $3.2 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Gross Profit slumped 104.3% in 2022, then jumped 1884.1% in 2023.
• Over 5 years, Gross Profit stood at -$178.0 million in 2022, then surged by 1884.1% to $3.2 billion in 2023, then advanced by 9.03% to $3.5 billion in 2024, then gained by 2.98% to $3.6 billion in 2025, then gained by 10.22% to $3.9 billion in 2026.
• The last three Gross Profit figures came in at $3.9 billion (Q2 2026), $3.2 billion (Q1 2026), and $3.6 billion (Q4 2025), per Business Quant data.